GelMEDIX Inc. has secured $397,000 in investment, marking a significant financial development for the early-stage biotechnology company. This capital infusion will support its ongoing efforts to develop innovative ocular and regenerative therapies aimed at restoring vision, leveraging its proprietary hydrogel platform.
GelMEDIX was founded after multiple years of academic collaboration between co-founders Reza Dana from Mass. Eye And Ear, Harvard Medical School, and Nasim Annabi of UCLA. The company's proprietary photo-crosslinked hydrogels are uniquely designed to enable bioadhesion, tissue regeneration, tunable mechanics, and therapeutic loading. This versatility allows the platform to be utilized across various modalities, from small molecules to cell and gene therapies.
The company's lead program focuses on an integrated hydrogel cell therapy specifically engineered to restore vision for macular degeneration patients with Dry AMD and Geographic Atrophy (GA). This funding round is crucial for advancing these critical research and development initiatives. GelMEDIX plans to use the funds for growth initiatives, primarily focused on accelerating the development of its hydrogel technology and lead therapeutic programs.
This investment underscores confidence in GelMEDIX's innovative platform and its potential to address significant unmet medical needs in ophthalmology. The capital is expected to accelerate the company's progress towards preclinical milestones, moving its vision-restoring therapies closer to clinical application and ultimately benefiting patients with severe sight-threatening conditions.
